TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Follow-Up Questions
¿Quién es el CEO de TELA Bio Inc?
Mr. Antony Koblish es el President de TELA Bio Inc, se unió a la empresa desde 2012.
¿Qué tal es el rendimiento del precio de la acción TELA?
El precio actual de TELA es de $1.62, ha increased un 1.94% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de TELA Bio Inc?
TELA Bio Inc pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de TELA Bio Inc?
La capitalización bursátil actual de TELA Bio Inc es $64.2M
¿Es TELA Bio Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 7 analistas han realizado calificaciones de análisis para TELA Bio Inc, incluyendo 3 fuerte compra, 6 compra, 2 mantener, 0 venta, y 3 fuerte venta
